{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Silence Therapeutics Plc"},"Symbol":{"label":"Symbol","value":"SLN"},"Address":{"label":"Address","value":"72 HAMMERSMITH ROAD, LONDON, W14 8TH, United Kingdom"},"Phone":{"label":"Phone","value":"+44 2034576900"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical needs. Its income consists of royalty income and revenue from collaboration agreements. Its geographical segments are the United Kingdom, the United States, and Germany."},"CompanyUrl":{"label":"Company Url","value":"https://www.silence-therapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Craig Allen Tooman","title":"President, CEO & Executive Director"},{"name":"Curtis Rambaran","title":"Chief Medical Officer"},{"name":"Marie Wikstr√∂m Lindholm","title":"Chief Scientific Officer"},{"name":"Steven Joseph Romano","title":"Head-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}